ReportWire

Tag: type 1 diabetes

  • Upcoming diabetes research fundraiser honors LI attorney | Long Island Business News

    [ad_1]

    An attorney with a law firm in Roslyn is the honoree of the 20th annual Cooking for a Cure fundraiser for the Miami-based Institute Foundation (DRIF).

    Jaime Greenberg, a partner of , practices domestic and international adoption and estate planning law. The Glen Cove resident and his family will be honored at the fundraiser at the in Bayville on Wednesday, April 22.

    “I can’t wait to do whatever we can to support the DRIF and help scientists build a cure,” Greenberg said in a news release about the fundraiser.

    For Greenberg, the effort is personal. His son Sean, now 21 and thriving, was diagnosed earlier with . A hockey player, he learned he had diabetes at Cohen’s Children’s Hospital after losing weight and drinking water excessively.

    Soon after, Jaime Greenberg discovered he had type 2 diabetes after a frightening incident.

    “I was driving, and I passed out while I was behind the wheel,” he said. “My blood sugar was through the roof. My mom was diabetic, so I always knew about diabetes, but I didn’t pick up on the signs for myself. It came out of left field.”

    Through his involvement in Glen Cove Junior Soccer – which he now leads as its president – Jaime met the event’s co-founder , now the minority leader of the Nassau County Legislature. They spoke frequently about their children and their respective experiences with type 1 diabetes.

    “I’ve been very involved the last couple of years, and I’m gaining greater understanding and following the breakthroughs,” Greenberg said. “My goal and hope someday is for Sean and everyone with diabetes to have something in their bodies so they don’t have to take insulin anymore.”

    Cooking for a Cure has raised more than $1.5 million for DRIF, supporting the institute’s work in cure- and prevention-focused diabetes research. Research includes efforts to regenerate the human pancreas and expand treatment therapies aimed at advancing a cure and prevention.

    “Whether he is on the soccer field, supporting families in the courtroom as an adoption specialist, advocating for our youth or supporting local businesses, Jaime has proven himself to be a passionate advocate for the causes that matter most – and there is nothing more important than the of our children and a diabetes-free future,” DeRiggi-Whitton said in the news release.

    “It has been a blessing to see Jaime and his son thrive after being diagnosed, and I am so proud to have the Greenberg family in our corner on this mission,” she added. I hope to see everyone on April 22 as we continue the fight for a cure.”

    Tickets are $125, and available here.


    [ad_2]

    Adina Genn

    Source link

  • Treat Type 1 Diabetes with a Plant-Based Diet?  | NutritionFacts.org

    Treat Type 1 Diabetes with a Plant-Based Diet?  | NutritionFacts.org

    [ad_1]

    Is it possible to reverse type 1 diabetes if caught early enough?

    The International Journal of Disease Reversal and Prevention has already had its share of miraculous disease reversals with a plant-based diet. For instance, one patient began following a whole food, plant-based diet after having two heart attacks in two months. Within months, he experienced no more chest pain, controlled his cholesterol, blood pressure, and blood sugars, and also lost 50 pounds as a nice bonus. Yet, the numbers “do not capture the patient’s transformation from feeling like a ‘dead man walking’ to being in command of his health with a new future and life.” 

    I’ve previously discussed cases of reversing the autoimmune inflammatory disease psoriasis and also talked about lupus nephritis (kidney inflammation). What about type 1 diabetes, an autoimmune disease we didn’t think we could do anything about? In contrast to type 2 diabetes, which is a lifestyle disease that can be prevented and reversed with a healthy enough diet and lifestyle, type 1 diabetes is an autoimmune disease in which our body attacks our pancreas, killing off our insulin-producing cells and condemning us to a life of insulin injections—unless, perhaps, it’s caught early enough. If a healthy enough diet is started early enough, might we be able to reverse the course of type 1 diabetes by blunting that autoimmune inflammation?

    As I discuss in my video Type 1 Diabetes Treatment: A Plant-Based Diet, we know that patients with type 1 diabetes “may be able to reduce insulin requirements and achieve better glycemic [blood sugar] control” with healthier diets. For example, children and teens were randomized to a nutritional intervention in which they increased the whole plant food density of their diet—meaning they ate more whole grains, whole fruits, vegetables, legumes (beans, split peas, chickpeas, and lentils), nuts, and seeds. Researchers found that the more whole plant foods, the better the blood sugar control.

    The fact that more whole fruits were associated “with better glycemic [blood sugar] control has important clinical implications for nutrition education” in those with type 1 diabetes. We should be “educating them on the benefits of fruit intake, and allaying erroneous concerns that fruit may adversely affect blood sugar.”

    The case series in the IJDRP, however, went beyond proposing better control of just their high blood sugars, the symptom of diabetes, but better control of the disease itself, suggesting the anti-inflammatory effects of whole healthy plant foods “may slow or prevent further destruction of the beta cells”—the insulin-producing cells of the pancreas—“if dietary intervention is initiated early enough.” Where did this concept come from?

    A young patient. Immediately following diagnosis of type 1 diabetes at age three, a patient began a vegetable-rich diet and, three years later, “has not yet required insulin therapy…and has experienced a steady decline in autoantibody levels,” which are markers of insulin cell destruction. Another child, who also started eating a healthier diet, but not until several months after diagnosis, maintains a low dose of insulin with good control. And, even if their insulin-producing cells have been utterly destroyed, individuals with type 1 diabetes can still enjoy “dramatically reduced insulin requirements,” reduced inflammation, and reduced cardiovascular risk, which is their number one cause of death over the age of 30. People with type 1 diabetes have 11 to 14 times the risk of death from cardiovascular disease compared to the general population, and it’s already the top killer among the public, so it’s closer to 11 to 14 times more important for those with type 1 diabetes to be on the only diet and lifestyle program ever proven to reverse heart disease in the majority of patients—one centered around whole plant foods. The fact it may also help control the disease itself is just sugar-free icing on the cake.

    All this exciting new research was presented in the first issue of The International Journal of Disease Reversal and Prevention. As a bonus, there’s a companion publication called the Disease Reversal and Prevention Digest. These are for the lay public and are developed with the belief I wholeheartedly share that “everyone has a right to understand the science that could impact their health.” You can go behind the scenes and hear directly from the author of the lupus series, read interviews from luminaries like Dean Ornish, see practical tips from dietitians on making the transition towards a healthier diet, and enjoy recipes. 

    The second issue includes more practical tips, such as how to eat plant-based on a budget, and gives updates on what Dr. Klaper is doing to educate medical students, what Audrey Sanchez from Balanced is doing to help change school lunches, and how Dr. Ostfeld got healthy foods served in a hospital. (What a concept!) And what magazine would be complete without an article to improve your sex life? 

    The journal is free, downloadable at IJDRP.org, and its companion digest, available at diseasereversaldigest.com, carries a subscription fee. I am a proud subscriber.

    Want to learn more about preventing type 1 diabetes in the first place? See the related posts below.

    [ad_2]

    Michael Greger M.D. FACLM

    Source link

  • CBD Provides Symptom Relief and Improvement in Gastroparesis – Medical Marijuana Program Connection

    CBD Provides Symptom Relief and Improvement in Gastroparesis – Medical Marijuana Program Connection

    [ad_1]

    Pharmaceutical-grade cannabidiol (CBD) relieved symptoms in patients with idiopathic and diabetic gastroparesis and increased tolerance of liquid nutrient intake after 4 weeks of treatment in a phase 2 randomized double-blinded, placebo-controlled study recently published in Clinical Gastroenterology and Hepatology.

    There is “significant unmet medical need in gastroparesis,” and compared with cannabis, which has been used to relieve nausea and pain in patients with the condition, CBD has limited psychic effects with the added potential to reduce gut sensation and inflammation, wrote Ting Zheng, MD, and colleagues at Mayo Clinic in Rochester, Minn.

    The researchers assessed the symptoms of 44 patients (21 randomized to receive CBD and 23 to receive placebo) – each of whom had nonsurgical gastroparesis with documented delayed gastric emptying of solids (GES) by scintigraphy for at least 3 months – with the American Neurogastroenterology and Motility Society’s Gastroparesis Cardinal Symptom Index (GCSI) Daily Diary.

    They measured GES at baseline, and at 4 weeks, they measured GES again as well as fasting and postprandial gastric volumes and satiation using a validated Ensure drink test. (Patients ingested Ensure [Abbott Laboratories] at a rate of 30 mL/min and recorded their sensations every 5 minutes.) The two treatment arms were compared via 2-way analysis of covariance that included body mass index and, when applicable,…

    [ad_2]

    MMP News Author

    Source link

  • KYT Launches Designer Bags for Diabetics

    KYT Launches Designer Bags for Diabetics

    [ad_1]

    KYT redefining diabetes by designing an innovative bag range that merges medicine and fashion.

    Diabetics now have their own designer bags to streamline their daily treatment. KYT, which stands for Keeping You Together, has revealed three new contemporary, premium bags purpose-built for the everyday needs of people with diabetes – a chronic condition that the World Health Organization (WHO) says affects 422 million people worldwide. 

    Crafted with the insights of hundreds of diabetics from around the world, the bags have innovative features, smart layouts, premium materials like gold-rated Italian leather and solid brass hardware, and ethical craftsmanship. A contemporary exterior discreetly hides diabetes supplies like a testing kit, pump consumables, and insulin pens. The bags now available for global pre-order are: 

    SideKYT: a contemporary crossbody bag that streamlines users’ essential diabetes supplies. The bag splits in two: life essentials up front and diabetes equipment out back. A testing station allows blood glucose levels to be tested straight from the bag.  

    SideKYT+: a larger crossbody built for pump users or those who want to take more equipment or spares. 

    StarterKYT: a compact case that lets users take their supplies on the sly. The size of a sunglasses case, it smartly locks together with magnets, unfolds completely flat to create a testing station, and then folds back together in a snap. 

    KYT is also committed to ethical production and materials, and a donation from every bag sold helps diabetes charities get crucial supplies to those in need.  

    At age 20, Designer & KYT Founder Bridget Scanlan was diagnosed with Type 1 Diabetes. As her pancreas stopped producing insulin, she had to learn to manage multiple blood glucose tests and insulin injections every day. Along with all the equipment that came with it.  

    “From talking to diabetics around the world, I got universal insights into the daily diabetes struggle,” Scanlan says. “It sparked a thought: could smarter design empower people to feel better about dealing with daily treatment? I wanted to redesign diabetes so we could all redefine it.”  

    Combining her background in fashion design and entrepreneurship, Scanlan was inspired to channel her chronic condition to help empower other diabetics by creating designer bags specifically for diabetics. 

    “Every zip, every angle, every equipment detail has been influenced by the insights gathered from the hundreds of incredible diabetics who have opened up and shared their diabetes stories (and gripes) with me,” Scanlan says.  

    According to WHO, globally 8.5% of adults aged 18 and older have diabetes, making it one of the most prevalent chronic conditions worldwide.    

    Stanford University research estimates that people managing diabetes make around 180 extra health-related decisions every day to keep themselves safe. 

    Here is some of the feedback from diabetics using KYT’s original Crossbody bag: 

    “I’ve been waiting 50 years for a bag like this….it is so easy to ‘keep me together.’ Pick it up and off I go, and no one knows what I am having to carry around.” – Joy, New Zealand Diabetic  

    “I am loving my KYT for travel! It’s such a great bag, I now take it with me whenever I go away.” – Megan, London Diabetic  

    “Cannot be more excited for this amazing bag designed for diabetics. Fully functional & more importantly so stylish!” – Kyoko, Tokyo Diabetic 

    For more information, please visit https://kytbags.com/. Photos can be downloaded from KYT’s media kit.   

    About KYT Diabetes Bags   

    KYT stands for KEEPING YOU TOGETHER. We’re redefining diabetes by redesigning it. With look-good, feel-good, do-good bags designed to help you feel great about doing diabetes on the daily. 

    Source: KYT Bags

    Related Media

    [ad_2]

    Source link

  • What’s New in Diabetes Treatment?

    What’s New in Diabetes Treatment?

    [ad_1]

    Advances in Diabetes Treatment


    By
    Camille Peri
    WebMD Feature

    Diabetes treatment is getting better every day. Scientists may be just a few years away from making an artificial pancreas that can safely detect and adjust blood sugar (glucose) levels. In the meantime, new medications and insulin devices can make living with diabetes easier and safer now.

    “We’re getting more and more options,” says Michael German, MD, clinical director of the Diabetes Center at the University of California, San Francisco. “That’s good because no two people with diabetes are the same. It helps us get the right medicine for each person.”

    Recommended Related to Diabetes


    Is There a Hypoglycemia Diet?

    If you’ve ever gone too long between meals to eat and suddenly felt shaky, lightheaded, anxious, and cranky, you’ve had hypoglycemia. These unpleasant symptoms are your body’s way of warning you that your blood sugar (glucose) levels have fallen too low. (That’s what “hypoglycemia” means.)
    Glucose is the body’s main source of energy. In most people, blood sugar levels should be within a range of 70 to 99 milligrams per deciliter (mg/dL).
    Most healthy people only need a quick high-carb snack, such…


    Read the Is There a Hypoglycemia Diet? article > >

    Progress in Diabetes Care

    These treatments are or will soon be available in the U.S.


    • Afrezza. This insulin inhaler for adults with type 1 and type 2 diabetes hit the market in February 2015. You use it at the beginning of a meal for a boost of short-acting insulin. Unlike an older inhaler, which was the size of a can of shaving cream, Afrezza is easier to use and not as clunky to carry around. “It’s quite small – a little bigger than a whistle,” says Sethu K. Reddy, MD, chief of adult diabetes at Joslin Diabetes Center at Harvard Medical School in Boston. It’s probably not for you if you smoke or have a lung condition like asthma or emphysema.


    • Medtronic MiniMed 640G. This combined insulin pump and continuous glucose monitor is a step toward the artificial pancreas. It automatically stops pumping insulin when your blood sugar levels are trending down and starts again when they’re back up. “Hypoglycemia [low blood sugar] is a real problem, particularly for people with type 1 diabetes,” German says. It could be especially useful for people who have hypoglycemia but feel no symptoms. The device isn’t available in the U.S. yet, but it may come to the FDA for approval soon. 


    • Lucentis. Doctors already use this drug to treat the eye disease macular edema in people who don’t have diabetes. But in February 2015, the FDA made it the first eye medication for diabetic retinopathy, a serious eye problem linked to diabetes and a leading cause of blindness among U.S. adults.

    [ad_2]

    Source link

  • What’s New in Diabetes Treatment?

    What’s New in Diabetes Treatment?

    [ad_1]

    Advances in Diabetes Treatment


    By
    Camille Peri
    WebMD Feature

    Diabetes treatment is getting better every day. Scientists may be just a few years away from making an artificial pancreas that can safely detect and adjust blood sugar (glucose) levels. In the meantime, new medications and insulin devices can make living with diabetes easier and safer now.

    “We’re getting more and more options,” says Michael German, MD, clinical director of the Diabetes Center at the University of California, San Francisco. “That’s good because no two people with diabetes are the same. It helps us get the right medicine for each person.”

    Progress in Diabetes Care

    These treatments are or will soon be available in the U.S.


    • Afrezza. This insulin inhaler for adults with type 1 and type 2 diabetes hit the market in February 2015. You use it at the beginning of a meal for a boost of short-acting insulin. Unlike an older inhaler, which was the size of a can of shaving cream, Afrezza is easier to use and not as clunky to carry around. “It’s quite small – a little bigger than a whistle,” says Sethu K. Reddy, MD, chief of adult diabetes at Joslin Diabetes Center at Harvard Medical School in Boston. It’s probably not for you if you smoke or have a lung condition like asthma or emphysema.


    • Medtronic MiniMed 640G. This combined insulin pump and continuous glucose monitor is a step toward the artificial pancreas. It automatically stops pumping insulin when your blood sugar levels are trending down and starts again when they’re back up. “Hypoglycemia [low blood sugar] is a real problem, particularly for people with type 1 diabetes,” German says. It could be especially useful for people who have hypoglycemia but feel no symptoms. The device isn’t available in the U.S. yet, but it may come to the FDA for approval soon. 


    • Lucentis. Doctors already use this drug to treat the eye disease macular edema in people who don’t have diabetes. But in February 2015, the FDA made it the first eye medication for diabetic retinopathy, a serious eye problem linked to diabetes and a leading cause of blindness among U.S. adults.

    [ad_2]

    Source link

  • Artificial Pancreas Device May Help Folks With Type 2 Diabetes

    Artificial Pancreas Device May Help Folks With Type 2 Diabetes

    [ad_1]

    By Denise Mann 

    HealthDay Reporter

     

    FRIDAY, Jan. 13, 2023 (HealthDay News) — An artificial pancreas has long been considered the holy grail for people with type 1 diabetes, and new research suggests a more convenient version of this technology may help the millions of people living with type 2 diabetes.

    Type 2 is the more common form of diabetes, and is closely linked to obesity.

    The pancreas produces insulin, the hormone that helps blood sugar (or glucose) enter cells to be used as energy.People with type 1 diabetes make little to no insulin. When insulin is in short supply, glucose builds up, causing extreme fatigue, blurry vision, weight loss and confusion. Some people with type 2 diabetes also need to take daily insulin to keep their blood sugar in check.

    Enter the artificial pancreas, an automated insulin delivery system that mimics the pancreas’ function.

    “About 20% to 30% of people living with type 2 diabetes use insulin therapy to manage their diabetes, and we have shown that this way of delivering insulin with a closed-loop system is much more effective than their current insulin injections at reaching glucose targets,” said study author Dr. Charlotte Boughton, a clinical lecturer at the University of Cambridge in England.

    With closed-loop systems for type 1 diabetes, the user enters information several times a day about the timing and size of their food intake, but insulin delivery between meals and overnight is automated. By contrast, the new system for people with type 2 diabetes is a fully closed loop. This means users don’t have to input any information.

    It was developed using over-the-counter devices, including an off-the-shelf glucose monitor and an insulin pump with an app called CamAPS HX. This software predicts how much insulin is needed to keep blood sugar levels in the target range. People wear the blood sugar sensor and insulin pump and carry a smartphone with them for the system to work, Boughton said.

    “This fully automated closed-loop system is a safe and much more effective way for people living with type 2 diabetes to manage their glucose levels than current standard treatment with insulin,” she said.

    Just how effective was it? When people with type 2 diabetes used the new system, they spent twice as much time with glucose levels in the target range than when they tested blood sugar and gave themselves insulin shots, the investigators found.

    Boughton said this is equivalent to an additional eight hours a day and was achieved without increasing the risk of dangerously low glucose levels.

    “We anticipate that the improvement in glucose control we have seen may reduce the risk of diabetes complications such as eye disease, kidney disease and amputations, but a much larger study with longer follow-up is required to investigate this,” she added.

    The new study included 26 people with type 2 diabetes. One group used the artificial pancreas for eight weeks and then switched to multiple daily insulin injections. The others were treated in the opposite order.

    On average, people using the artificial pancreas were within their target blood sugar range two-thirds of the time. This is double what was seen with standard insulin shots, according to the report.

    What’s more, people delivering insulin via shots spent two-thirds of their time with high glucose levels, compared with 33% when using the artificial pancreas, the researchers found.

    The system also helped reduce levels of glycated hemoglobin, or HbA1c, which provides a snapshot of blood sugar levels over time.

    No one in the study experienced dangerously low blood sugar, or hypoglycemia, which can occur if the device doesn’t keep blood sugar levels in the target range.

    And then there is the quality-of-life improvement that comes with not needing to constantly check blood sugar levels, inject insulin or take medication. Nine of 10 participants said they spent less time managing their diabetes when they used the artificial pancreas.

    This technology could be game-changing for millions.

    “The number of people diagnosed with type 2 diabetes is increasing globally, and people are diagnosed at a younger age, so they are living with type 2 diabetes for longer,” Boughton said. “Anyone with type 2 diabetes who struggles to keep glucose levels where they should be with insulin injections could benefit from this system.”

    The devices do cost more than standard insulin injections and glucose testing kits.

    “If the closed-loop system can reduce the risk of very expensive diabetes complications in the long-term — such as the need for dialysis, visual impairment and amputations — then they may be cost-effective. But a much larger study with longer follow-up is required to investigate this,” Boughton stressed.

    The researchers have previously shown that an artificial pancreas run by a similar algorithm is effective for those with type 1 diabetes and have also tested this system in people with type 2 diabetes who require kidney dialysis.

    These systems can be fairly simple to use: You wear the devices, load them with insulin and go about your daily routine, explained Dr. John Buse, chief of endocrinology and director of the Diabetes Center at the University of North Carolina at Chapel Hill.

    “No such device is available in the U.S. or, to my knowledge, anywhere in the world,” said Buse, who reviewed the new study.

    Similar investigational technologies cost about $10,000 per year for the devices, supplies, insulin and provider support, he said. “[They cost] more in the first year with acquisition costs and less over time,” he explained.

    More research is needed before this device is ready for prime time, but the promise is real, Buse added.

    “Keeping glucose in a relatively narrow range holds the promise of reducing long-term complications of diabetes — blindness, kidney failure, amputations, heart attacks, strokes, as well as minimizing the risk of urgent hospitalization related to high or low glucose, as well as potentially reduced risk of infection, cognitive decline and other important issues common in diabetes,” he said.

    The findings were published online Jan. 11 in Nature Medicine.

    More information

    Learn more about the artificial pancreas at the U.S. National Institute of Diabetes and Digestive and Kidney Diseases.

     

    SOURCES: Charlotte Boughton, PhD, clinical lecturer, University of Cambridge, U.K.; John Buse, MD, PhD, professor, medicine, director, Diabetes Center and N.C. Translational and Clinical Sciences Institute, University of North Carolina, Chapel Hill; Nature Medicine, Jan. 11, 2023, online

    [ad_2]

    Source link

  • Biosimilars May Finally Stop the Rocketing Cost of Insulin

    Biosimilars May Finally Stop the Rocketing Cost of Insulin

    [ad_1]

    Oct. 26, 2022 Trapper Haskins, a 45-year-old musician with type 1 diabetes, says the price of insulin is a constant stressor in his life. The Nashville resident takes two types of insulin daily and sometimes must ration the medicine because his insurance plan caps how much of the pricey drug he can receive each month. Insulin “isn’t like a high blood pressure medication,” he says. “Some days you need more, and then you get to the end of the month and you’re afraid you’ll run out.” 

    Research shows that among people with type 1 and type 2 diabetes, about one in four must ration their supplies due to cost. In general, most people with diabetes need two or three vials of insulin a month. Each vial can cost hundreds of dollars, meaning patients’ costs could easily reach $1,000 a month 

    “The price of insulin has tripled in the last 10 years, and it’s creating a national crisis,” says Lizheng Shi, PhD, a professor of health policy at Tulane University in New Orleans.          .

    There are 1.5 million people with type 1 diabetes in the U.S. who can’t buy their own insulin and are entirely dependent on it to keep their blood sugar in a safe range. The vast majority of people with diabetes, some 37 million, have type 2 diabetes, which usually results in the use of blood sugar-reducing medications until insulin is introduced later on because the body no longer responds to its own. 

    The high cost of insulin is largely due to a lack of competition and too few makers of the current products, says Shi. One of the best hopes for more affordable insulin is to increase market competition and drive down prices with the introduction of so-called biosimilar drugs, which are highly similar versions of the original biologic medications – and typically far less expensive. 

    Creating Competition in the Market 

    In July 2021, the FDA approved the first biosimilar product that could be used interchangeably with current insulin products. Called Semglee, it’s a long-acting insulin analog and the generic form of Lantus, the world’s leading basal insulin, whose patent expired in 2016. Semglee, which is made by the drug company Mylan, is now available under some 2022 insurance plans and is approved for patients with type and type 2 diabetes. But Semglee isn’t inexpensive – it’s around $133 per vial without insurance. Some versions of Lantus retail for more than $300. 

    The introduction of insulin biosimilars won’t bring major price cuts anytime soon,  says Jing Luo, MD, an assistant professor of medicine at the University of Pittsburgh. One reason, he says, is that it takes years for drugmakers to develop  the expertise and capacity to scale up production of biosimilars. Still, Luo is optimistic that we’ll get there in the next 2-3 years, and once we do, it could mean insulin would cost 10 times less. 

    Luo cites  the work of the nonprofit Civica Rx. In March, the organization announced it would produce large-scale generic insulin in an effort to drive down cost. 

    The company will produce three forms of insulin to be used interchangeably with Lantus, Humalog, and Novolog. The products will be sold for no more than $30 a vial. They’ve already started building their manufacturing plant in Petersburg, VA, and will have products available for purchase by 2024, pending FDA approval.

    Additionally, the state of California plans to produce its own generic insulin. The state is investing $50 million to make biosimilar insulin products and another $50 million to build a manufacturing facility. 

    Not Soon Enough

    But for many, price cuts aren’t happening fast enough. Allison Bailey of Ames, IA, who has type 1 diabetes, says that it can feel daunting sometimes to find a way to pay, but she couldn’t survive without the life-saving medication. At times, it’s cost her up to $500 to fill her prescription. Bailey was eventually able to adjust her prescription to a less expensive insulin, but the 35-year-old graphic designer says her insurance coverage still takes up a sizable chunk of her monthly expenses.

    The introduction of biosimilars has not driven down the price of insulin fast enough for patients like Bailey, says Robert A. Gabbay, MD, PhD, chief science and medical officer at the American Diabetes Association. That’s why the association is pushing legislation to bring down insulin prices. It lobbied hard to establish a $35-per-month Medicare price cap that will go into effect in 2023. Now it’s focused its efforts on expanding the caps to private insurers, a move that was voted down by Republicans in Congress as part of the Inflation Reduction Act. 

    “We want to see some transparency in pricing; right now, everyone just points fingers at each other and we don’t know who’s to blame,” Gabbay says. 

    But people with diabetes like Haskins and Bailey agree that competition from biosimilars and price caps could help bring down what they view as the exorbitant prices for medications they need. “I’m lucky I have insurance, but for those who don’t, it’s often a life-or-death situation,” says Haskins

    [ad_2]

    Source link